Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to target KRAS downstream effectors PI3K and mTOR. In this study,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Ning, Changwen, Liang, Min, Liu, Shuang, Wang, Guan, Edwards, Holly, Xia, Yang, Polin, Lisa, Dyson, Gregory, Taub, Jeffrey W., Mohammad, Ramzi M., Azmi, Asfar S., Zhao, Lijing, Ge, Yubin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546481/
https://ncbi.nlm.nih.gov/pubmed/28574828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17869
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak